Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.86) by 8.14 percent. This is a 17.91 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $6.252 million which missed the analyst consensus estimate of $16.607 million by 62.35 percent. This is a 66.12 percent decrease over sales of $18.453 million the same period last year.